vTv Therapeutics (VTVT) Expected to Announce Earnings on Wednesday

vTv Therapeutics (NASDAQ:VTVT) is anticipated to issue its results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.21 per share and revenue of $20.00 million for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. On average, analysts expect vTv Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

vTv Therapeutics Stock Down 0.7%

VTVT opened at $30.46 on Tuesday. The firm has a market cap of $120.01 million, a PE ratio of -9.09 and a beta of 0.26. The business has a fifty day simple moving average of $36.08 and a 200-day simple moving average of $33.79. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00.

Wall Street Analyst Weigh In

VTVT has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Friday, March 27th. Roth Mkm assumed coverage on vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price on the stock. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. BTIG Research restated a “buy” rating and set a $49.00 target price on shares of vTv Therapeutics in a report on Wednesday, March 11th. Finally, Evercore assumed coverage on vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VTVT. Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $221,000. Finally, 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $731,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.